Therapeutic Options for Visceral Leishmaniasis

被引：0
作者：
Begoña Monge-Maillo
Rogelio López-Vélez
机构：
[1] Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS),Tropical Medicine and Clinical Parasitology, Infectious Diseases Department, Ramón y Cajal Hospital
来源：
Drugs | 2013年 / 73卷
关键词：
Allopurinol; Visceral Leishmaniasis; Leishmaniasis; Pentamidine; Liposomal Amphotericin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection, malnourishment and other concomitant infections. This article provides an exhaustive review of the literature regarding studies published on the treatment of VL, and gives therapeutic recommendations stratified according to their level of evidence, the species of Leishmania implicated and the geographical location of the infection.
引用
收藏
页码：1863 / 1888
页数：25
相关论文
共 500 条
  • [21] Tleyjeh IM(2006)Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study Indian J Pediatr 73 1077-69
  • [22] Kish MA(2011)Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh Am J Trop Med Hyg 85 66-550
  • [23] Torrus D(2012)Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use Clin Infect Dis 55 543-2403
  • [24] Boix V(2003)Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug Antimicrob Agents Chemother 47 2397-39
  • [25] Massa B(2006)Mechanisms of experimental resistance of Drug Resist Updat 9 26-1538
  • [26] Portilla J(2013) to miltefosine: implications for clinical use Clin Infect Dis 56 1530-364
  • [27] Perez-Mateo M(2013)Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance Am J Trop Med Hyg 89 750-598
  • [28] Kager PA(2006)In vitro susceptibility of Leishmania donovani to miltefosine in indian visceral leishmaniasis Clin Infect Dis 43 357-213
  • [29] Rees PH(2002)A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection Curr Opin Infect Dis 15 593-110
  • [30] Wellde BT(1983)Advances in the treatment of leishmaniasis Lancet 1 210-1561
12345678910